Biblio

Found 400 results
Author [ Keyword(Desc)] Title Type Year
Filters: Author is Andreas du Bois  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
*Brachytherapy Combined Modality Therapy Endometrial Neoplasms/*radiotherapy/surgery Female Humans Hysterectomy Neoplasm Staging *Physician's Practice Patterns Radiation Oncology/*standards Radiotherapy
W. Small, du Bois, A., Bhatnagar, S., Reed, N. Simon, Pignata, S., Potter, R., Randall, M., Mirza, M., Trimble, E. L., Gaffney, D. K., and InterGroup, G. Cancer, Practice patterns of radiotherapy in endometrial cancer among member groups of the Gynecologic Cancer Intergroup, Int J Gynecol Cancer, vol. 19, pp. 395-9, 2009.
80 and over Antineoplastic Agents/pharmacology Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use Carboplatin/administration & dosage Cisplatin/pharmacology Deoxycytidine/administration & dosage/analogs & derivatives Disease
J. Pfisterer, Plante, M., Vergote, I. B., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G. C. E., Kimmig, R., Olbricht, S., Le, T., Emerich, J., Kuhn, W., Bentley, J., Jackisch, C., Luck, H. J., Rochon, J., Zimmermann, A. Hayden, Eisenhauer, E., -OVAR, A. G. O., -CTG, N. C. I. C., and -GCG, E. O. R. T. C., Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG, J Clin Oncol, vol. 24, pp. 4699-707, 2006.
80 and over Antineoplastic Agents/therapeutic use Female Gynecologic Surgical Procedures/*mortality Humans Middle Aged Neoplasm Recurrence
J. Pfisterer, Harter, P., Canzler, U., Richter, B., Jackisch, C., Hahmann, M., Hasenburg, A., Burges, A., Loibl, S., Gropp, M., Huober, J., Fink, D., du Bois, A., Committee, A. G. O. Ovarian, and Group, A. G. O. Ovarian Ca, The role of surgery in recurrent ovarian cancer, Int J Gynecol Cancer, vol. 15 Suppl 3, pp. 195-8, 2005.
80 and over Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carboplatin/administration & dosage Cisplatin/administration & dosage Female Humans Middle Aged Neoplasm Staging Ovarian Neoplasms/*drug therapy/pathology Paclitaxel/administrati
P. Wimberger, Lehmann, N., Kimmig, R., Burges, A., Meier, W., Hoppenau, B., du Bois, A., and -OVAR, A. G. O., Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR), Gynecol Oncol, vol. 100, pp. 300-7, 2006.
80 and over Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/*therapeutic use Carboplatin/administration & dosage Disease-Free Survival Drug Administration Schedule Female France Germany Humans Middle Aged Ovarian Ne
J. Pfisterer, Weber, B., Reuss, A., Kimmig, R., du Bois, A., Wagner, U., Bourgeois, H., Meier, W., Costa, S., Blohmer, J. - U., Lortholary, A., Olbricht, S., Stähle, A., Jackisch, C., Hardy-Bessard, A. C., Möbus, V., Quaas, J., Richter, B., Schröder, W., Geay, J. - F., Luck, H. J., Kuhn, W., Meden, H., Nitz, U., Pujade-Lauraine, E., -OVAR, A. G. O., and , Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO, J Natl Cancer Inst, vol. 98, pp. 1036-45, 2006.
Adjuvant Cisplatin/therapeutic use Female Gynecology/*standards Health Care Surveys Humans Hysterectomy *Physician's Practice Patterns Radiation Oncology/*standards Radiation-Sensitizing Agents/therapeutic use Radiotherapy Dosage Uterine Cervical Neoplas
D. K. Gaffney, du Bois, A., Narayan, K., Reed, N. Simon, Toita, T., Pignata, S., Blake, P., Portelance, L., Sadoyze, A., Potter, R., Colombo, A., Randall, M., Mirza, M. R., and Trimble, E. L., Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG), Int J Radiat Oncol Biol Phys, vol. 68, pp. 485-90, 2007.
Adjuvant Female Humans Hypercalcemia/*pathology Hysterectomy Middle Aged Neoplasm Staging Ovarian Neoplasms/blood/*classification/pathology/*therapy Ovariectomy Radiotherapy
M. L. Harrison, Hoskins, P., du Bois, A., Quinn, M., Rustin, G. J. S., Ledermann, J. A., Baron-Hay, S., and Friedlander, M. Leonard, Small cell of the ovary, hypercalcemic type – analysis of combined experience and recommendation for management. A GCIG study, Gynecol Oncol, vol. 100, pp. 233-8, 2006.
Adult
F. Heitz, du Bois, A., Harter, P., Lubbe, D., Kurzeder, C., Vergote, I. B., Plante, M., and Pfisterer, J., Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG., Gynecol Oncol, vol. 129, no. 3, pp. 463-6, 2013.
J. Pfisterer, Weber, B., Reuss, A., Kimmig, R., du Bois, A., Wagner, U., Bourgeois, H., Meier, W., Costa, S., Blohmer, J. - U., Lortholary, A., Olbricht, S., Stähle, A., Jackisch, C., Hardy-Bessard, A. - C., Möbus, V., Quaas, J., Richter, B., Schröder, W., Geay, J. - F., Lück, H. - J., Kuhn, W., Meden, H., Nitz, U., and Pujade-Lauraine, E., Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO., J Natl Cancer Inst, vol. 98, no. 15, pp. 1036-45, 2006.
E. Pujade-Lauraine, Wagner, U., Åvall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., Volgger, B., Vergote, I. B., Pignata, S., Ferrero, A., Sehouli, J., Lortholary, A., Kristensen, G. B., Jackisch, C., Joly, F., Brown, C., Le Fur, N., and du Bois, A., Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse., J Clin Oncol, vol. 28, no. 20, pp. 3323-9, 2010.
J. Pfisterer, Vergote, I. B., du Bois, A., and Eisenhauer, E., Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer., Int J Gynecol Cancer, vol. 15 Suppl 1, pp. 36-41, 2005.
M. L. Harrison, Hoskins, P., du Bois, A., Quinn, M., Rustin, G. J. S., Ledermann, J. A., Baron-Hay, S., and Friedlander, M. Leonard, Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study., Gynecol Oncol, vol. 100, no. 2, pp. 233-8, 2006.
S. Mahner, Meier, W., du Bois, A., Brown, C., Lorusso, D., Dell'Anna, T., Cretin, J., Havsteen, H., Bessette, P., Zeimet, A. G., Vergote, I. B., Vasey, P. A., Pujade-Lauraine, E., Gladieff, L., and Ferrero, A., Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial., Eur J Cancer, vol. 51, no. 3, pp. 352-8, 2015.
S. Pecorelli, Ray-Coquard, I., Tredan, O., Colombo, N., Parma, G., Tisi, G., Katsaros, D., Lhommé, C., Lissoni, A., Vermorken, J. B., du Bois, A., Poveda, A. M., Frigerio, L., Barbieri, P., Carminati, P., Brienza, S., and Guastalla, J. P., Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes., Ann Oncol, vol. 21, no. 4, pp. 759-65, 2010.
J. Pfisterer, Plante, M., Vergote, I. B., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G. C. E., Kimmig, R., Olbricht, S., Le, T., Emerich, J., Kuhn, W., Bentley, J., Jackisch, C., Lück, H. - J., Rochon, J., Zimmermann, A. Hayden, and Eisenhauer, E., Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG., J Clin Oncol, vol. 24, no. 29, pp. 4699-707, 2006.
A. du Bois, Weber, B., Rochon, J., Meier, W., Goupil, A., Olbricht, S., Barats, J. - C., Kuhn, W., Orfeuvre, H., Wagner, U., Richter, B., Lueck, H. - J., Pfisterer, J., Costa, S., Schröder, W., Kimmig, R., and Pujade-Lauraine, E., Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial. , J Clin Oncol, vol. 24, no. 7, pp. 1127-35, 2006.
P. Harter, Sehouli, J., Reuss, A., Hasenburg, A., Scambia, G., Cibula, D., Mahner, S., Vergote, I. B., Reinthaller, A., Burges, A., Hanker, L., Pölcher, M., Kurzeder, C., Canzler, U., Petry, K. Ulrich, Obermair, A., Petru, E., Schmalfeldt, B., Lorusso, D., and du Bois, A., Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO., Int J Gynecol Cancer, vol. 21, no. 2, p. 295, 2011.

Pages